Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience.

ABSTRACT:

Background

It is critically important to study the real-world data of FDA-approved medications to understand the response rates and toxicities observed in the real-world population not represented in the clinical trials.

Methods

We reviewed charts of patients diagnosed with metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 negative, PIK3CA-mutated breast cancer treated with alpelisib from May 2019 to January 2022. Clinical characteristics and treatment outcomes were collected. The association of clinical characteristics with responses and adverse events (AEs) was evaluated using the logistic regression model.

Results

27 patients were included. Median age at alpelisib initiation 67 years (range: 44, 77 years). Majority of patients had exce

SUBMITTER: Alaklabi S 

PROVIDER: S-EPMC9631302 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature